ModernVivo

Executive Summary

ModernVivo addresses a critical bottleneck in preclinical research: the time-consuming and error-prone process of literature review for in vivo study design. Its AI-powered platform automatically extracts and synthesizes key experimental parameters—such as animal models, dosing regimens, and endpoints—from thousands of scientific papers. This enables researchers at drug discovery companies, contract research organizations (CROs), academic labs, and IACUC committees to design more efficient and effective studies, reducing duplication and accelerating the path to clinical trials. By automating data synthesis, ModernVivo aims to cut study design time from weeks to hours, ultimately improving reproducibility and decision-making in preclinical development. Founded in 2018 and headquartered in Cambridge, MA, ModernVivo is currently in the pre-clinical stage as a private company. While it has yet to disclose funding rounds or revenue, its platform addresses a clear industry pain point with growing demand for AI-driven tools in biotech. The company faces competition from other literature-mining platforms but differentiates through its focus on in vivo parameters and integration with study planning workflows. If successful, ModernVivo could become an essential infrastructure layer for preclinical research, potentially reducing drug development costs and timelines. However, the lack of disclosed traction and its early stage introduce uncertainty around adoption and scalability.

Upcoming Catalysts (preview)

• Q3 2026Series A funding round announcement60% success
• Q1 2027Partnership with a top pharmaceutical company or major CRO40% success
• Q4 2026Release of an upgraded AI model with enhanced accuracy and new features70% success